---
title: "Nurix Therapeutics, Inc. Stock 12‑Month Price Target Raised to $32.12, Implies 30% Upside"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292284867.md"
description: "Nurix Therapeutics' 12-month average price target was raised to $32.12 from $31.44, implying a 30% upside based on the July 9 closing price. This update reflects estimates from 16 analysts, with targets ranging between $23 and $45. The consensus rating remains 'Buy', comprising 15 buy ratings, 1 hold, and no sell ratings."
datetime: "2026-07-10T07:20:08.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292284867.md)
  - [en](https://longbridge.com/en/news/292284867.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292284867.md)
generator: "portal-rs"
---

# Nurix Therapeutics, Inc. Stock 12‑Month Price Target Raised to $32.12, Implies 30% Upside

-   According to estimates from 16 analysts, Nurix Therapeutics, Inc. stock's average price target has risen from $31.44 to $32.12, with forecasts ranging from $23 to $45 per share
-   Based on the Jul. 9 closing price, the updated target implies approximately 30% potential upside
-   Consensus rating remains at “Buy” across 16 covering analysts, with 15 Buys, 1 Holds and 0 Sells

Explore more price target data and ratings for Nurix Therapeutics, Inc. on the , and track all previous and future analyst recommendations for Nurix Therapeutics, Inc. in the dedicated News Flow.

**Disclaimer**

Select reference data provided by FactSet. Copyright © 2026 FactSet Research Systems Inc. This information is not a recommendation for what you should do personally and does not constitute investment advice.

### Related Stocks

- [NRIX.US](https://longbridge.com/en/quote/NRIX.US.md)
- [FDS.US](https://longbridge.com/en/quote/FDS.US.md)

## Related News & Research

- [Nurix Therapeutics, Inc. Stock 12‑Month Price Target Raised to $32.5, Implies 32% Upside](https://longbridge.com/en/news/292361447.md)
- [Nurix Therapeutics, Inc. Stock 12‑Month Price Target Raised to $32.87, Implies 42% Upside](https://longbridge.com/en/news/292982845.md)
- [Apnimed, Inc. reports Q2 results](https://longbridge.com/en/news/298366495.md)
- [Braveheart Bio, Inc. reports Q2 results](https://longbridge.com/en/news/298361396.md)
- [Nektar Therapeutics (NKTR) Lands Lancet Backing, Is The Upside Already Priced In?](https://longbridge.com/en/news/298137481.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**